First, the detailed molecular mechanisms and signaling pathways through which CDKN1B influences the clinical outcomes of breast cancer, using our bioinformatics approach and in silico analysis, need to be experimentally validated. This evidence concerns the gene CDKN1B and breast carcinoma.